Key Highlights

  • Starpharma shares have risen 568.18% over the past year, trading at $0.74 as at 3 September 2026
  • FY26 Revenue increased 145% to $12.0 million, driven primarily by an $8.3 million upfront payment from the Genentech licence agreement
  • FY26 reported loss improved 25% to $7.5 million, even as Research and Development expenditure rose to $11.1 million
  • The company ended FY26 with $11.0 million in cash and subsequently raised a further $30 million net through an Entitlement Offer

Shares of Starpharma Holdings Limited (ASX:SPL) were trading at $0.74 on 3 September 2026, up 2.08%, or 1.5 cents, in the session as at 4:10pm AEST. Over the preceding twelve months, the stock has gained 568.18%, a move that reflects a period of considerable investor attention following the company's licensing activity and financial results.

FY26 Financial Results

Starpharma released its Annual Report and full-year financial results for the year ended 30 June 2026 on 26 August 2026. FY26 revenue increased 145% to $12.0 million, up from $4.9 million in FY25, driven primarily by an $8.3 million upfront payment received from the Genentech licence agreement. Revenue also included product sales, royalties, and other licence and research revenue.

The company's FY26 reported loss improved by 25% to $7.5 million, compared with $10.0 million in FY25. Research and product development expenditure rose to $11.1 million, up from $8.4 million in FY25, net of the Australian Government's R&D tax incentive, reflecting continued Investment in the company's DEP pipeline, including its DEP HER2-Lutetium radiopharmaceutical asset and other early-stage next-generation DEP programs.

Cash Position and Funding

Starpharma ended FY26 with a cash balance of $11.0 million. Subsequent to year-end, the company raised net proceeds of $30 million through a widely supported Entitlement Offer, which the company said strengthens its cash position and extends its funding runway into FY28.

Pipeline and Strategic Progress

Chief Executive Officer Cheryl Maley said the company had significantly advanced its lead radiopharmaceutical asset, DEP HER2-Lutetium, during FY26, while executing new strategic partnerships and strengthening existing ones. She said the year further validated the broad potential of the company's DEP technology, with a continued focus on targeted oncology treatments.

Starpharma describes itself as an innovative biotechnology company with two decades of experience advancing dendrimer technology from the laboratory to the patient. Its portfolio includes clinical-stage DEP assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter products. Dendrimers are described by the company as precise, synthetically manufactured, nanoscale molecules whose size, structure, branching, polyvalency and water solubility are advantageous in medical and pharmaceutical applications.

Conclusion

Starpharma's FY26 results show a marked increase in revenue, driven substantially by the upfront payment associated with its Genentech licence agreement, alongside a narrower reported loss even as research and development spending increased to support its DEP pipeline. The subsequent $30 million Entitlement Offer extends the company's funding runway into FY28, providing Capital to continue advancing its lead radiopharmaceutical asset and other early-stage programs. Following a year in which the stock delivered a substantial gain, continued progress on strategic partnerships and pipeline milestones is likely to remain the focus for those tracking the company going forward.